These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 30768680)

  • 1. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.
    Socié G; Caby-Tosi MP; Marantz JL; Cole A; Bedrosian CL; Gasteyger C; Mujeebuddin A; Hillmen P; Vande Walle J; Haller H
    Br J Haematol; 2019 Apr; 185(2):297-310. PubMed ID: 30768680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab in pregnancy: a narrative overview.
    Sarno L; Tufano A; Maruotti GM; Martinelli P; Balletta MM; Russo D
    J Nephrol; 2019 Feb; 32(1):17-25. PubMed ID: 30159857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab.
    Servais A; Devillard N; Frémeaux-Bacchi V; Hummel A; Salomon L; Contin-Bordes C; Gomer H; Legendre C; Delmas Y
    Nephrol Dial Transplant; 2016 Dec; 31(12):2122-2130. PubMed ID: 27587606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S; Hidaka Y; Inoue N; Kaname S; Kato H; Matsumoto M; Miyakawa Y; Mizuno M; Okada H; Shimono A; Matsuda T; Maruyama S; Fujimura Y; Nangaku M; Kagami S
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan.
    Nishimura JI; Kawaguchi T; Ito S; Murai H; Shimono A; Matsuda T; Fukamizu Y; Akiyama H; Hayashi H; Nakano T; Maruyama S
    Int J Hematol; 2023 Oct; 118(4):419-431. PubMed ID: 37515657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort.
    Mallett A; Hughes P; Szer J; Tuckfield A; Van Eps C; Cambell SB; Hawley C; Burke J; Kausman J; Hewitt I; Parnham A; Ford S; Isbel N
    Intern Med J; 2015 Oct; 45(10):1054-65. PubMed ID: 26247170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.
    Bozio CH; Isenhour C; McNamara LA
    PLoS One; 2020; 15(11):e0241989. PubMed ID: 33180804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases.
    Tanaka K; Fujita N; Hibino S
    CEN Case Rep; 2020 Aug; 9(3):247-251. PubMed ID: 32240525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab.
    Gäckler A; Kaulfuß M; Rohn H; Vogel U; Claus H; Feldkamp T; Kribben A; Witzke O
    Nephrol Dial Transplant; 2020 Feb; 35(2):298-303. PubMed ID: 29992261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab.
    Reher D; Fuhrmann V; Kluge S; Nierhaus A
    Vaccine; 2018 May; 36(19):2507-2509. PubMed ID: 29631884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
    Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
    Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis.
    Benamu E; Montoya JG
    Curr Opin Infect Dis; 2016 Aug; 29(4):319-29. PubMed ID: 27257797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future pharmacologic complement inhibitors.
    Risitano AM
    Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.